Royalty Pharma plc (Nasdaq: RPRX) has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions